
Wednesday, June 18, 2025 2:52:15 PM
Recent TPTW News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2025 05:25:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2025 06:11:19 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 10:01:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2025 08:59:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2025 07:37:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2025 06:48:29 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/07/2025 06:45:52 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/07/2025 06:44:43 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/07/2025 06:42:40 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/07/2025 06:42:10 PM
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 12/26/2024 09:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2024 09:58:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/04/2024 11:06:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 07:43:09 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/10/2024 06:46:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 02:03:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 03:02:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/25/2024 06:39:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 08/12/2024 05:39:45 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM